Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02395627
Title Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pamela Munster

estrogen-receptor positive breast cancer


Pembrolizumab + Tamoxifen + Vorinostat

Age Groups: adult
Covered Countries USA

No variant requirements are available.